JCR Pharmaceuticals Statistics

Total Valuation

JCR Pharmaceuticals has a market cap or net worth of JPY 71.27 billion. The enterprise value is 81.75 billion.

Market Cap	71.27B
Enterprise Value	81.75B

Important Dates

The next estimated earnings date is Friday, January 31, 2025.

Earnings Date	Jan 31, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

JCR Pharmaceuticals has 121.82 million shares outstanding. The number of shares has decreased by -0.32% in one year.

Current Share Class	n/a
Shares Outstanding	121.82M
Shares Change (YoY)	-0.32%
Shares Change (QoQ)	+0.29%
Owned by Insiders (%)	0.28%
Owned by Institutions (%)	15.17%
Float	71.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	16.64
PS Ratio	2.07
PB Ratio	1.29
P/TBV Ratio	1.33
P/FCF Ratio	71.13
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 34.86, with an EV/FCF ratio of 81.59.

EV / Earnings	-187.08
EV / Sales	2.32
EV / EBITDA	34.86
EV / EBIT	n/a
EV / FCF	81.59

Financial Position

The company has a current ratio of 1.65, with a Debt / Equity ratio of 0.50.

Current Ratio	1.65
Quick Ratio	0.90
Debt / Equity	0.50
Debt / EBITDA	8.54
Debt / FCF	28.36
Interest Coverage	-1.86

Financial Efficiency

Return on equity (ROE) is -0.71% and return on invested capital (ROIC) is -0.15%.

Return on Equity (ROE)	-0.71%
Return on Assets (ROA)	-0.12%
Return on Capital (ROIC)	-0.15%
Revenue Per Employee	37.75M
Profits Per Employee	-467,880
Employee Count	934
Asset Turnover	0.34
Inventory Turnover	0.48

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -48.16% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-48.16%
50-Day Moving Average	660.74
200-Day Moving Average	662.34
Relative Strength Index (RSI)	34.32
Average Volume (20 Days)	373,845

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, JCR Pharmaceuticals had revenue of JPY 35.26 billion and -437.00 million in losses. Loss per share was -3.50.

Revenue	35.26B
Gross Profit	25.19B
Operating Income	-203.00M
Pretax Income	-435.00M
Net Income	-437.00M
EBITDA	3.33B
EBIT	-203.00M
Loss Per Share	-3.50

Full Income Statement

Balance Sheet

The company has 18.27 billion in cash and 28.41 billion in debt, giving a net cash position of -10.14 billion or -83.24 per share.

Cash & Cash Equivalents	18.27B
Total Debt	28.41B
Net Cash	-10.14B
Net Cash Per Share	-83.24
Equity (Book Value)	57.05B
Book Value Per Share	451.83
Working Capital	22.17B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.68 billion and capital expenditures -3.68 billion, giving a free cash flow of 1.00 billion.

Operating Cash Flow	4.68B
Capital Expenditures	-3.68B
Free Cash Flow	1.00B
FCF Per Share	8.22

Full Cash Flow Statement

Margins

Gross margin is 71.44%, with operating and profit margins of -0.58% and -1.24%.

Gross Margin	71.44%
Operating Margin	-0.58%
Pretax Margin	-1.23%
Profit Margin	-1.24%
EBITDA Margin	9.43%
EBIT Margin	-0.58%
FCF Margin	2.84%

Dividends & Yields

This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 3.38%.

Dividend Per Share	20.00
Dividend Yield	3.38%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.32%
Shareholder Yield	3.70%
Earnings Yield	-0.60%
FCF Yield	1.41%

Dividend Details

Stock Splits

The last stock split was on September 29, 2020. It was a forward split with a ratio of 4.

Last Split Date	Sep 29, 2020
Split Type	Forward
Split Ratio	4

Scores

JCR Pharmaceuticals has an Altman Z-Score of 2.45. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.45
Piotroski F-Score	n/a